Moreover, the 36-month beta value for NEO is 1.23. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for NEO is 126.80M and currently, short sellers hold a 2.86% of that float. On November 28, 2024, NEO’s average trading volume was 747.08K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NEO) stock’s latest price update
The stock price of Neogenomics Inc (NASDAQ: NEO) has jumped by 3.26 compared to previous close of 17.18. Despite this, the company has seen a gain of 15.49% in its stock price over the last five trading days. globenewswire.com reported 2024-11-25 that TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) — NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that the Company will be holding a corporate webinar on Thursday, December 5, 2024, at 7 PM EDT / 4 PM PDT / 9 AM KT.
NEO’s Market Performance
Neogenomics Inc (NEO) has seen a 15.49% rise in stock performance for the week, with a 31.21% gain in the past month and a 8.04% surge in the past quarter. The volatility ratio for the week is 4.17%, and the volatility levels for the past 30 days are at 4.35% for NEO. The simple moving average for the last 20 days is 13.35% for NEO’s stock, with a simple moving average of 18.83% for the last 200 days.
Analysts’ Opinion of NEO
Many brokerage firms have already submitted their reports for NEO stocks, with Craig Hallum repeating the rating for NEO by listing it as a “Buy.” The predicted price for NEO in the upcoming period, according to Craig Hallum is $26 based on the research report published on May 01, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NEO reach a price target of $21, previously predicting the price at $25. The rating they have provided for NEO stocks is “Buy” according to the report published on December 29th, 2023.
Stephens gave a rating of “Overweight” to NEO, setting the target price at $18 in the report published on August 21st of the previous year.
NEO Trading at 20.77% from the 50-Day Moving Average
After a stumble in the market that brought NEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.40% of loss for the given period.
Volatility was left at 4.35%, however, over the last 30 days, the volatility rate increased by 4.17%, as shares surge +31.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.78% upper at present.
During the last 5 trading sessions, NEO rose by +15.49%, which changed the moving average for the period of 200-days by +24.06% in comparison to the 20-day moving average, which settled at $15.65. In addition, Neogenomics Inc saw 9.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NEO starting from Olivo Alicia C, who sale 5,175 shares at the price of $15.36 back on Nov 15 ’24. After this action, Olivo Alicia C now owns 37,129 shares of Neogenomics Inc, valued at $79,475 using the latest closing price.
ALICIA OLIVO, the Officer of Neogenomics Inc, proposed sale 5,175 shares at $15.79 during a trade that took place back on Nov 15 ’24, which means that ALICIA OLIVO is holding shares at $81,713 based on the most recent closing price.
Stock Fundamentals for NEO
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.42 for the gross margin
The net margin for Neogenomics Inc stands at -0.12. The total capital return value is set at -0.07. Equity return is now at value -8.38, with -4.68 for asset returns.
Based on Neogenomics Inc (NEO), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at 0.03. The debt to equity ratio resting at 0.59. The interest coverage ratio of the stock is -13.24.
Currently, EBITDA for the company is -17.61 million with net debt to EBITDA at -556.44. When we switch over and look at the enterprise to sales, we see a ratio of 3.91. The receivables turnover for the company is 4.25for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
To wrap up, the performance of Neogenomics Inc (NEO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
